ALB and cancer: Our data indicate that thisapproach can be an effective way to enhance HSA-DTX@PEG-DVL NP cytotoxicityto TNBC cancer cells via targeting with DVL, considering that thesecells lack membrane surface targeting receptors to perform immunoreactivetherapy.